TITLE

Drug design: Increasing stability of ADCs

AUTHOR(S)
Crunkhorn, Sarah
PUB. DATE
November 2014
SOURCE
Nature Reviews Drug Discovery;Nov2014, Vol. 13 Issue 11, p812
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the importance of maleimide in improving the stability of antibody-drug conjugates (ADCs) for the treatment of cancer.
ACCESSION #
99713827

 

Related Articles

  • Antibody therapy of cancer. Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J. // Nature Reviews Cancer;Apr2012, Vol. 12 Issue 4, p278 

    The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The...

  • Better Therapeutic Index May Help Conquer Cell Division. Breindl, Anette // BioWorld Today;4/10/2013, Vol. 24 Issue 68, p1 

    The article discusses Mitotic Checkpoints Strategies Driving Cancer Strategies, a session where researchers discussed several ways to improve therapeutic index. Improving targeting through antibody-drug conjugates (ADCs) and exploiting synthetic lethal strategies are cited as two ways to improve...

  • OXFORD BIOTHERAPEUTICS OBTAINS RIGHTS XENOMOUSE.  // Worldwide Biotech;Jun2014, Vol. 26 Issue 6, p3 

    The article reports that Oxford BioTherapeutics won the exclusive global rights to ImmunoGen's maytansinoid antibody drug conjugates (ADC) technology and some Xenomouse antibodies produced by Amgen. Topics covered include the existing strategic partnership between Amgen and Oxford...

  • Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer -- Webcast scheduled for May 23.  // Biomedical Market Newsletter;5/5/2012, Vol. 21, p1 

    The article presents information on a clinical research study to be released by Celldex Therapeutics Inc. This study is related to CDX-011, an antibody drug conjugate (ADC) that contains a human monoclonal antibody, in patients with advanced breast cancer. This ADC was licensed from Seattle...

  • Celldex Breast Cancer ADC Bid Goes Pivotal in Triple-Negative. Osborne, Randy // BioWorld Today;12/3/2013, Vol. 24 Issue 231, p1 

    The article discusses the pivotal study called METRIC by biopharmaceutical company Celldex Therapeutics Inc. as a result of the positive data gathered from its Phase II trial of antibody-drug conjugate (ADC) glembatumumab vedotin (CDX-011) in patients with metastatic, triple-negative breast...

  • Linomide and Antibody-Targeted Superantigen Therapy Abolishes Formation of Liver Metastases in Mice. Liu, Q.; Klintman, D.; Corbascio, M.; Ekberg, H.; Hedlund, G.; Forsberg, G.; Thorlacius, H. // European Surgical Research;Nov/Dec2003, Vol. 35 Issue 6, p457 

    Hematogenous spread of tumor cells and metastasis formation in the liver are insidious aspects of cancer progression and are not frequently amenable to curative treatment. We examined the effect of Linomide and antibody-targeted therapy against the formation of hepatic metastases in vivo. For...

  • Celldex's CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article informs about the phase IIb trial of CDX-011 antibody drug conjugate by Celldex Therapeutics Inc. in patients expressing glycoprotein NMB (GPNMB) and pretreated breast cancer. It informs about the overall response rate on treatment with CDX-011 in patients with GPNMB and triple...

  • Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies. Chiarella, Pieranna // Recent Patents on Anti-Cancer Drug Discovery;May2011, Vol. 6 Issue 2, p258 

    Since the advent of hybridoma technology 35 years ago, research on monoclonal antibodies has developed enormously. Monoclonal antibodies of mouse origin were the first to be produced and continue to be the most popular affinity reagents for investigating the proteome of all organisms. For their...

  • Targeted Cancer Therapy by Immunoconjugated Gold-Gold Sulfide Nanoparticles Using Protein G as a Cofactor. Sun, Xinghua; Zhang, Guandong; Patel, Dhruvinkumar; Stephens, Dennis; Gobin, Andre // Annals of Biomedical Engineering;Oct2012, Vol. 40 Issue 10, p2131 

    Gold-gold sulfide nanoparticles (GGS-NPs) fabricated from chloroauric acid and sodium thiosulfate show unique near infrared (NIR) absorption that renders them as a promising candidate for photothermal cancer therapy. To improve targeting efficiency, we developed a versatile method to allow...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics